HCW Biologics is trading 6.25% down in pre-market at $1.05, compared with its November 2 close of $1.12; no clear company-specific catalyst has been identified.

  • Recent price context shows volatility, including a 6.78% decline on October 30.
  • The company’s release page lists an October 9 update as its latest news release, with no November 3 announcement shown.
  • Broader market context is mixed and does not clearly explain the decline.